Tapentadol
Osteoarthritis
Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Janssen Scientific Affairs, LLC
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01631513CT.gov An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR) | — | Withdrawn | — | — | — |
NCT00982280CT.gov Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability. | — | Terminated | — | — | — |
NCT00983073CT.gov Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic | — | Completed | — | — | — |
NCT00487435CT.gov An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain | — | Completed | — | — | — |
NCT00364546CT.gov A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteoarthritis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tapentadol (this asset) | Janssen Scientific Affairs, LLC | Approved | BB · 71 |
| Buprenorphine | Mundipharma Pte Ltd. | P4 | BBB |
| Naltrexone | Brigham and Women's Hospital | P4 | BBB |
| Oxycodone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P4 | BBB |
| Fentanyl | Janssen Pharmaceutica | P4 | BBB |
| Liraglutide | Henrik Gudbergsen | P4 | BBB |
| Duloxetine | The Catholic University of Korea | P4 | BBB |
| Triamcinolone Hexacetonide | Kastamonu University | P4 | BB |
| Dextrose Solution | Kastamonu University | P4 | BB |
+39 more in the Osteoarthritis cohort
Other indications for Tapentadol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Vertebral Column Disorder | — | P4 | BB · 67 |
| Diabetic Neuropathy | — | P3 | BB · 65 |
| Chronic Pain Syndrome | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Tapentadol in Osteoarthritis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/tapentadol-osteoarthritis-26657
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →